Glucotrack, Inc. 10-Q

Item 1. Financial Statements GLUCOTRACK INC. CONDENSED CONSOLIDATED BALANCE SHEETS (i n thousands of US dollars except share data) September 30, 2024 December 31, 2023 Unaudited ASSETS Current assets Cash and cash equivalents $ 346 $ 4,492 Other current assets 296 376 Total current assets 642 4,868 Operating lease right-of-use asset, net (Note 3C) 65 - Property and equipment, net 109 27 Restricted cash 10 10 TOTAL ASSETS $ 826 $ 4,905 LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY Current liabilities Accounts payable $ 1,857 $ 839 Operating lease liability, current (Note 3C) 25 - Promissory notes (Note 3G and Note 3H) 1,988 - Convertible promissory notes (Note 3F) 5 - Derivative financial liabilities (Note 3G and Note 3H) 37 - Other current liabilities 699 673 Total current liabilities 4,611 1,512 Non-current liabilities Loans from stockholders 197 196 Operating lease liability, non-current (Note 3C) 40 - Total liabilities 4,848 1,708 Commitments and contingent liabilities (Note 4) - Stockholders’ equity Common Stock of $ 0.001 par value (“Common Stock”): 100,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 5,772,026 and 4,178,274 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 6 4 Common Stock of $ 0.001 par value (“Common Stock”):100,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 5,772,190 and 4,178,274 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 6 4 Additional paid-in capital 118,223 112,982 Receipts on account of shares 100 48 Accumulated other comprehensive income 5 16 Accumulated deficit ( 122,356 ) ( 109,853 ) Total stockholders’ (deficit) equity ( 4,022 ) 3,197 TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY $ 826 $ 4,905 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 4 GLUCOTRACK INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands of US dollars except share data) (unaudited) 2024 2023 2024 2023 Three-month period ended September 30, Nine-month period ended September 30, 2024 2023 2024 2023 Research and development expenses $ 2,063 $ 1,693 $ 7,800 $ 2,962 Marketing expenses 125 - 295 - General and administrative expenses 1,063 531 2,598 1,725 Total operating expenses 3,251 2,224 10,693 4,687 Operating loss 3,251 2,224 10,693 4,687 Other income ( 12 ) - ( 12 ) - Finance (income) expenses, net (Note 5) 1,848 ( 1 ) 1,822 ( 2 ) Net Loss 5,087 2,223 12,503 4,685 Other comprehensive (income) loss: Foreign currency translation adjustment 17 ( 6 ) 11 ( 17 ) Comprehensive loss for the period $ 5,104 $ 2,217 $ 12,514 $ 4,668 Basic and diluted net loss per common stock $ ( 0.91 ) $ ( 0.49 ) $ ( 2.39 ) $ ( 1.38 ) Weighted average number of common stock used in computing basic and diluted loss per common stock 5,594,880 4,593,733 5,355,806 4,006,527 The accompanying notes are an integral part of these condensed interim consolidated financial statements. 5 GLUCOTRACK INC. CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (in thousands of US Dollars except share data) (unaudited) In thousands of US Dollars (except share data) Common Stock Additional Receipts Accumulated Other Total Stockholders’ Numbers of Shares Amount Paid-in Capital on account of shares Comprehensive Income Accumulated Deficit Equity (Deficit) Balance as of January 1, 2023 3,099,982 $ 3 $ 103,107 $ 4 $ 17 $ ( 101,901 ) $ 1,230 Loss for the period - - - - - ( 4,685 ) ( 4,685 ) Other comprehensive income - - - - 17 - 17 Stock-based compensation - - 260 - - 260 Deemed dividend resulted from trigger of down round protection feature of certain warrants granted - - 855 - - ( 855 ) - Issuance of Common Stock and pre-funded warrants upon completion of public offering, net of offering expenses 1,075,294 1 8,729 - - - 8,730 Issuance of restricted shares as compensation towards directors 2,998 - ( *) 9 ( 4 ) - - 5 Balance as of September 30, 2023 4,178,274 $ 4 $ 112,960 $ - $ 34 $ ( 107,441 ) $ 5,557 Balance at July 1, 2023 4,178,274 $ 4 $ 112,929 $ - $ 28 $ ( 105,218 ) $ 7,743 Loss for the period - - - - - ( 2,223 ) ( 2,223 ) Other comprehensive income - - - - 6 - 6 Stock-based compensation - - 31 - - - 31 Balance as of September 30, 2023 4,178,274 $ 4 $ 112,960 $ - $ 34 $ ( 107,441 ) $ 5,557 Balance as of January 1, 2024 4,178,274 $ 4 $ 112,982 $ 48 $ 16 $ ( 109,853 ) $ 3,197 Loss for the period - - - - - ( 12,503 ) ( 12,503 ) Other comprehensive income - - - - ( 11 ) - ( 11 ) Stock-based compensation - - 239 - - - 239 Issuance of restricted shares as compensation towards directors 86,861 (*) 126 ( 48 ) - - 78 Restricted shares to be issued as compensation towards directors - - - 100 - - 100 Exercise of prefunded warrants into shares (Note 3A) 395,294 (*) - - - - - Exchange of warrants into shares (Note 3B) 718,641 1 ( 1 ) - - - - Issuance of Common Stock upon private placement transaction (Note 3D) 79,366 (*) 500 - - - 500 Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H) - - 2,635 - - - 2,635 Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) 293,590 1 1,742 - - - 1,743 Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B) 20,000 - - - - - - Balance as of September 30, 2024 5,772,026 $ 6 $ 118,223 $ 100 $ 5 $ ( 122,356 ) $ ( 4,022 ) Balance as of July 1, 2024 5,478,436 $ 5 $ 113,903 $ 50 $ 22 $ ( 117,269 ) $ ( 3,289 ) Balance 5,478,436 $ 5 $ 113,903 $ 50 $ 22 $ ( 117,269 ) $ ( 3,289 ) Loss for the period - - - - - ( 5,087 ) ( 5,087 ) Other comprehensive income - - - - ( 17 ) - ( 17 ) Stock-based compensation - - 11 - - - 11 Restricted shares to be issued as compensation towards directors - - - 50 - - 50 Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H) - - 2,567 - - - 2,567 Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) 293,590 1 1,742 - - - 1,743 Balance as of September 30, 2024 5,772,026 $ 6 $ 118,223 $ 100 $ 5 $ ( 122,356 ) $ ( 4,022 ) Balance 5,772,026 $ 6 $ 118,223 $ 100 $ 5 $ ( 122,356 ) $ ( 4,022 ) (*) Represents amount lower than $1. The accompanying notes are an integral part of these condensed interim consolidated financial statements. 6 GLUCOTRACK INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands of US Dollars) (Unaudited) 2024 2023 Nine-month period ended September 30, 2024 2023 CASH FLOWS FROM OPERATING ACTIVITIES Loss for the period $ ( 12,503 ) $ ( 4,685 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 22 21 Stock-based compensation 239 260 Issuance of restricted shares as compensation towards directors 178 5 Linkage difference on principal of loans from stockholders 1 4 Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note 3J) 1,505 - Revaluation expenses related to derivative financial liabilities (Note 3H) 2 - Discount amortization and interest expenses related to promissory notes (Note 3F, Note 3G and Note 3H) 330 - Changes in assets and liabilities: Other current assets 80 ( 216 ) Accounts payable 1,129 598 Other current liabilities 26 ( 134 ) Net cash used in operating activities ( 8,991 ) ( 4,147 ) CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment ( 104 ) - Net cash used in investing activities ( 104 ) - CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds received from private placement transaction (Note 3D) 500 - Issuance of promissory notes and detachable warrants through private placement transaction (Note 3F) 100 - Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G) 360 - Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H) 4,000 - Net proceeds received from underwritten U.S. public offering - 8,730 Net cash provided by financing activities 4,960 8,730 Effect of exchange rate changes on cash and cash equivalents, and restricted cash ( 11 ) ( 17 ) Change in cash and cash equivalents, and restricted cash ( 4,146 ) 4,566 Cash and cash equivalents, and restricted cash at beginning of the period 4,502 2,331 Cash and cash equivalents, and restricted cash, end of period $ 356 $ 6,897 Supplemental disclosure of cash flow activities: (a) Net cash (received) paid during the year for: Interest $ ( 37 ) $ - (b) Non-cash investment and financing activities: Deemed dividend upon trigger of down round protection $ - $ 855 Recognition of right for use asset against a lease liability (Note 3C) $ 79 $ - Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) $ 238 $ - The accompanying notes are an integral part of these condensed interim consolidated financial statements. 7 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars, except share and per share data) NOTE 1 - GENERAL A. Glucotrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on development of an Implantable Continuous Glucose Monitor (CGM) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes (the “Glucotrack CBGM Product”). B. Liquidity and capital resources To date, the Company has not yet commercialized the Glucotrack CBGM Product. Further development and commercialization efforts are expected to require substantial additional expenditure. Therefore, the Company is dependent upon external sources for financing its operations. As of September 30, 2024, the Company has incurred an accumulated deficit of $ 122,356 . in addition, the Company has generated operating losses and negative operating cash flow for all reported periods. As of September 30, 2024, the balance of cash and cash equivalents amounted to $ 346 , together with the net proceeds in total amount of $ 8,873 which expected to be received upon closing of a public offering through registration statements on Form S-1 (see also Note 6 below) on November 14, 2024. During the year ended December 31, 2023, the Company raised net proceeds of $ 8,730 through completion of underwritten public offering. Moreover, during the period of nine months ended September 30, 2024, the Company entered into (i) exchange agreement with certain shareholders under which warrants with down round protection feature have been exchanged into shares of common stock in order to facilitate its equity structure (see also Note 3B below), (ii) private placement agreement under which the Company raised proceeds of $ 500 (see also Note 3D below), (iii) unsecured promissory notes and warrant agreements under which the Company raised proceeds of $ 100 (see also Note 3F below), (iv) unsecured promissory notes under which the Company raised proceeds of $ 360 (see also Note 3G below), (v) secured promissory note and warrant agreements under which the Company raised proceeds of $ 4,000 (see also Note 3H below) and (vi) conversion agreements under which certain financial liabilities have been settled for issuance of shares of common stock and warrants of the Company (see also Note 3I and Note 3J below ). The Company plans to finance its operations through the sale of equity securities (including shelf registration statement on Form S-3 was declared effective on October 3, 2023 by the Securities and Exchange Commission (SEC) which allows the Company to register up to $ 30,000 of certain equity and/or debt securities of the Company through prospectus supplement) and/or debt securities. There can be no assurance that the Company will succeed in obtaining the necessary financing or generating sufficient revenue from sale of its Glucotrack CBGM Product in order to continue its operations as a going concern. Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed interim consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. 8 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A. Basis of Presentation The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company’s consolidated financial statements and related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (“SEC”) on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature. The results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period. B. Use of Estimates in the Preparation of Financial Statements The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments. C. Principles of Consolidation The condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. D. Cash and Cash Equivalents Cash equivalents are short-term highly liquid investments which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. E. Modification of equity-classified contracts The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share. 9 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) F. Convertible Promissory Notes Upon initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40, “Derivatives and Hedging - Contracts in Entity’s Own Equity” (“ASC 815-40”) in order to determine whether the conversion features embedded within the convertible instrument should be separated from the host instrument. When it is determined that an embedded derivative required to be bifurcated (such as embedded conversion feature that does not qualify for equity classification), the Company recognized the embedded derivative bifurcated as a separate derivative liability upon initial recognition and on subsequent periods at fair value. The remaining consideration amount received or allocated to the entire convertible instrument is allocated to the host debt instrument. The difference between the face value of the host and such an allocated amount represents a discount which is amortized as finance expense to profit or loss using an effective interest method over the term of the note until its stated maturity. When it is determined that the embedded conversion feature qualifies for equity classification (such when the embedded conversion option, if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, “Derivatives and Hedging” since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the entity’s own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal amount that will be paid at maturity). When it is determined that a substantial premium exists, the entire premium is allocated to paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is accounted for at amortized cost using effective interest method over the term of the note until its stated maturity. G. Allocation of proceeds and related issuance costs When multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated among the individual freestanding instruments identified. The allocation occurs after identifying all freestanding instruments and the subsequent measurement basis for those instruments. Financial instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based on the relative fair value basis for such instruments. Issuance costs allocated to financial instruments that are required to be subsequently measured at fair value immediately expensed. Issuance costs allocated to shares and warrants classified as equity components and are recorded as a reduction of additional paid-in capital. Issuance costs allocated to financial liabilities measured at amortized cost are recorded as a discount and accreted over the contractual term of the financial instrument using the effective interest method. 10 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) H. Warrants Certain warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus, are considered as indexed to the Company’s own shares. As such warrants were issued together with financial instruments that are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants were deducted from additional paid-in capital. I. Leases The Company applies ASC Topic 842, “Leases” (“ASC 842”) under which the Company determines if an arrangement is a lease at inception. Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company’s lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases. Right of Use (“ROU”) assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company’s leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (“IBR”) based on the information available on the commencement date in determining the present value of lease payments. The Company’s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, “Property, Plant, and Equipment - Overall”, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. 11 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) J. Basic and diluted loss per share Basic loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period and upon exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method” and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants. Shares to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result of the exercise or conversion of these instruments was anti-dilutive. The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of three and nine months ended September 30, 2024 and 2023, is as follows: SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE 2024 2023 2024 2023 US dollars (except share data) US dollars (except share data) Three-month period ended September 30, Nine-month period ended September 30, (Unaudited) (Unaudited) 2024 2023 2024 2023 Numerator: Net loss $ 5,087 $ 2,223 $ 12,503 $ 4,685 Deemed dividend related to trigger of down round protection feature - - - 855 Net loss attributable to common stockholders $ 5,087 $ 2,223 $ 12,503 $ 5,540 Denominator: Shares of Common Stock used in computing basic and diluted net loss per common stock 5,564,880 4,593,733 5,340,532 3,758,590 Shares of Common Stock to be issued upon exercise of pre-funded warrants - - - 241,246 Shares of Common Stock to be issued upon achievement of performance milestones 30,000 - 15,275 6,691 Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share 5,594,880 4,593,733 5,355,806 4,006,527 Basic and diluted net loss per common stock $ ( 0.91 ) $ ( 0.49 ) $ ( 2.39 ) $ ( 1.38 ) 12 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 3 - SIGNIFICANT TRANSACTIONS A. Exercise of pre-funded warrants On January 3, 2024, 395,294 pre-funded warrants granted through underwritten public offering in April 2023 have been fully exercised into the same number of shares of Common Stock of the Company. B. Exchange Agreement On February 13, 2024, the Company entered into an Exchange Agreement with certain warrant holders (the “Holders”), pursuant to which the Company and the Holders agreed to exchange (the “Exchange”) warrants with down round protection feature exercisable to common shares (the “Warrants”) owned by the Holders for shares of Common Stock to be issued by the Company. On February 15, 2024, 718,641 shares of Common Stock have been issued in exchange for 876,391 Warrants (the “Shares”). It was also agreed that the Holders will not, during the period (“Lock-Up Period”) (i) offer, pledge, announce the intention to sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction specific in clause (i), (ii) or (iii) above, provided that the Holder, during the Lock-Up Period, may (a) sell or contract to sell Shares at a price higher than $0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than $0.80 per Share on any trading day with no volume limitation. The Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above $ 1.00 per Share for five consecutive trading days. The Company accounted for the Exchange of the aforesaid warrants with shares as deemed dividend which was calculated at the closing date by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity instrument (common shares) was estimated as lesser than the fair value of the replaced equity instrument, deemed dividend was not recorded. C. Lease Agreement On February 19, 2024, the Company entered into Lease Agreement (the “Agreement”) with Tapsak Enterprises LLC dba Virginia Analytical (the “Landlord”) under which it was agreed that the Company will lease from the Landlord a premises located in Front Royal, Virginia area for a monthly rental fee of $ 2.5 over a period of 3 -years commencing March 1, 2024 through February 28, 2027 (the “Initial Lease Period”). Security deposit of $ 2.5 which represents payment of one month is held by the Landlord which will be return to the Company at the end of the Initial Lease Period. In addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the Initial Lease Period (the “Option Term”), following advanced notice as defined in the Agreement. The monthly rental fee over the Option Term shall be the fair market rate determined as what is a comparable cost for similar property in Front Royal, Virginia area. In accordance with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to use asset equals to lease liability in total amount of $ 79 . The lease liability was measured at the present value of the future lease payments, which are discounted based on an estimate of the incremental interest rate that the Company would be required to pay to borrow a similar amount for a similar period in order to obtain a similar amount on the initial recognition date of the lease. As part of the leasing period, the Company considered only the Initial Lease Period as the realization of the option to extend the period was not considered as reasonably certain. 13 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) C. Lease Agreement (Cont.) Operating lease: SCHEDULE OF OPERATING LEASE September 30, 2024 Operating right-of-use asset $ 65 Current operating lease liability $ 25 Non-Current operating lease liability $ 40 Maturity analysis of the Company’s lease liability: SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY September 30, 2024 Less than one year $ 30 Between 1-2 years 30 More than 2 years 13 Total operating lease payments $ 73 Less: imputed interest $ 8 Present value of lease liabilities $ 65 Additional information on lease The following is a summary of the weighted average remaining lease terms and discount rate for the lease: SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE September 30, 2024 Lease term (years) 2.42 Weighted average discount rate 9.03 % D. Private Placement Agreement On April 22, 2024, the Company entered into a private placement agreement under which the Company issued 79,366 shares of its common stock at a price of $ 6.30 per share for aggregate gross proceeds of $ 500 (the “Offering”). The Offering included participation of certain members of the Company’s executive management, Board of Directors and existing shareholders. E. Adoption of 2024 Equity Incentive Plan and Reverse Share Split On April 26, 2024, the Company held its Annual Meeting of Shareholders (the “Annual Meeting”) under which the Company’s stockholders approved, inter alia, the following proposals: (i) adoption of the Company’s 2024 Equity Incentive Plan and (ii) an amendment to Article IV of the Company’s Certificate of Incorporation, to effect a reverse stock split of the Company’s Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board of Directors. Following the Annual Meeting, on April 30, 2024, the Company’s Board of Directors approved a one-for-five reverse stock split of the Company’s issued and outstanding shares of common stock (the “Reverse Stock Split”). On May 17, 2024, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation with the Secretary of State of the State of Delaware which effected the Reverse Stock Split. For accounting purposes, all shares, options and warrants to purchase shares of common stock and loss per share amounts have been adjusted to give retroactive effect to the Reverse Share Split for all periods presented in these interim consolidated financial statements. Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share. 14 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) F. Note and Warrant Purchase Agreements On June 27, 2024, the Company entered into note and warrant purchase agreements (the “Purchase Agreement”) with certain investors (the “June 27 Investors”), providing for the private placement of unsecured promissory notes in the aggregate principal amount of $ 100 (the “June 27 Notes” and each a “June 27 Note”) and warrants to purchase up to an aggregate of 300,000 shares of the Company’s Common Stock (the “June 27 Warrants”). The June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess of $1,000 (the “Maturity Date”). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash. Each of June 27 Warrants has an exercise price of $ 4.95 per share. The June 27 Warrants are immediately exercisable and have a 5-year term. Upon initial recognition, the management allocated the gross cash proceeds received based on the relative fair value of the June 27 Notes and the detachable June 27 Warrants in total amount of $ 15 and $ 85 , respectively. The fair value of the June 27 Note was determined based on a rating model using a debt discount rate of 28.65 % which represented the Company’s applicable rate of risk. The fair value of the June 27 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock price volatility of 245 % and risk-free interest rate of 4.52 %. The amount allocated to June 27 Warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price). The June 27 Notes are accounted for as a financial liability measured at amortized cost. In subsequent periods, the Company recognized a discount and interest expense over the economic life of the June 27 Notes based on the effective interest rate method. The following tabular presentation reflects the reconciliation of the carrying amount of the June 27 Notes during the period of nine months ended September 30, 2024: SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES Nine-month period ended September 30, 2024 (Unaudited) Open balance $ - Total proceeds received 100 Total proceeds allocated to June 27 Warrants at initial recognition ( 85 ) Discount amortization and interest expenses related to June 27 Notes (Note 5 below) 16 Partial conversion June 27 Notes and accrued Interest (Note 3I and Note 3J below) ( 26 ) Ending balance $ 5 During the period commencing the issuance date through September 30, 2024, none of the June 27 Warrants have been exercised. 15 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) G. Convertible Promissory Notes On July 18, 2024, the Company entered into a series of convertible promissory notes with three directors, and one member of the Company’s executive management (the “July 18 Investors”), providing for the private placement of unsecured convertible promissory notes in the aggregate principal amount of $ 360 (the “July 18 Notes” and each a “July 18 Note”). The July 18 Notes bear simple interest at a rate of 8 % per annum. Interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and payable on (i) the 12-month anniversary of the date hereof, or (ii) the closing date of a Qualified Financing, as defined herein (the “Maturity Date”). Except regarding the conversion of the July 18 Notes as discussed below, the Company may not prepay the July 18 Notes without the written consent of the July 18 Investors. If not sooner repaid, all outstanding principal and accrued but unpaid interest on the July 18 Notes (the “July 18 Note Balance”), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $ 500 (excluding indebtedness converted in such financing) (a “Qualified Financing”), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the July 18 Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $ 1.56 . Upon the occurrence of an Event of Default (as defined below), each July 18 Investors may, by written notice to the Company, declare the July 18 Note to be due immediately and payable with respect to the July 18 Note Balance. An “Event of Default” means (i) failure by the Company to pay the July 18 Note Balance on the Maturity Date, (ii) voluntary bankruptcy, or (iii) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 18 Note Balance shall automatically and immediately become due and payable, in all cases without any action on the part of any July 18 Investors. Upon initial date, the management measured the fair value of the embedded conversion feature which is accounted for as embedded derivative liability. The difference between the total gross cash proceeds received and the fair value of the embedded conversion feature is allocated to July 18 Notes that are measured at amortized cost under which in subsequent periods the Company recognizes a discount expense over the economic life of the July 18 Notes based on the effective interest rate method. However, the fair value of the embedded derivative liability related to the conversion feature was determined by the management at an insignificant amount since upon closing of a Qualified Financing the conversion will be done based on market conditions (i.e. conversion price will be equal to the fair value of the share upon conversion) and thus all proceeds received of $ 360 were allocated to the July 18 Notes. The following tabular presentation reflects the reconciliation of the carrying amount of the July 18 Notes during the period of nine months ended September 30, 2024: SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES Nine-month period ended September 30, 2024 (Unaudited) Open balance $ - Total proceeds allocated to July 18 Notes at initial recognition 360 Interest expenses related to July 18 Notes (Note 5 below) 5 Partial conversion July 18 Notes and accrued Interest (Note 3J below) ( 101 ) Ending balance $ 264 16 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) H. Convertible Promissory Note and Warrant Agreements On July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the “July 30 Warrants”) with an existing investor (the “July 30 Holder”), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of $ 4,000 (the “July 30 Note”). The July 30 Note is not convertible until and unless approved at a meeting of the Company’s stockholders (the “Stockholder Approval”). The July 30 Note bears simple interest at a rate of 8 % per annum and is due and payable in cash on earlier of: (i) 12 months anniversary of July 30 Note, or (ii) closing date of a Sale Transaction (defined below) (the “Maturity Date”) . The July 30 Note is secured by a first-priority security interest on all Company’s assets. Except regarding the conversion of the July 30 Note or a Sale Transaction as discussed below, the Company may not prepay the July 30 Note without the written consent of the July 30 Holder. If Stockholder Approval is obtained, the July 30 Note (i) is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the date of conversion and, (ii) if the Closing Price of the Common stock exceeds $ 5.00 per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted Average Price (“VWAP”) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split, combination or similar transaction). Upon Sale Transaction on or prior to the Maturity Date, the Company will repay the July 30 Holder, at the July 30 Holder’s election, as follows: (i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale Transaction if the July 30 Note was converted pursuant to an optional conversion. “Sale Transaction” means a merger or consolidation of the Company with or into any other entity, or a sale of all or substantially all of the Company’s assets, or any other transaction or series of related transactions in which the Company’s stockholders immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent. Upon the occurrence of an Event of Default (defined below), the July 30 Holder may, by written notice to the Company, declare the Note to be due immediately and payable with respect to the July 30 Note balance. An “Event of Default” means (i) failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than $ 50,000 , (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the July 30 Holder. Each July 30 Warrant becomes exercisable 12 months after its issuance and has term of 10 years. The July 30 Warrants are exercisable for cash only and have no price-based antidilution. The first July 30 Warrant is for 2,133,334 shares at $ 1.875 per share. The second July 30 Warrant is for 1,523,810 shares at $ 2.625 per share. The third July 30 Warrant is for 1,185,186 shares at $ 3.375 per share. At the initial date, the Company has issued two instruments that include (i) a financial instrument that is considered as “host” which comprised of July 30 Note and two embedded derivative financial instruments (i.e. an embedded conversion feature and an embedded redemption feature to receive cash equals to 200 % of July 30 Note balance upon Sale Transaction) and (ii) three series of detachable warrants. At the initial date, the Company is required to estimate the fair value of both two instruments and allocate the total gross proceeds received between them based on that relative fair value identified. The fair value of the embedded derivative financial instruments (i.e. the conversion right and the redemption right) should be bifurcated from the host instrument and remeasured on recurring basis at each reporting period under marked to market approach, the July 30 Note is accounted for under carrying amount whereby discount and interest expenses are recorded over the economic life of the July 30 Note based on the effective interest rate method and the July 30 Warrants are classified into equity without any further subsequent measurement. 17 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) H. Convertible Promissory Note and Warrant Agreements (Cont.) Upon initial recognition, the management by using the assistance of an external appraiser allocated the gross cash proceeds received based on the relative fair value of the July 30 Note and the detachable July 30 Warrants in total amount of $ 1,450 and $ 2,550 , respectively. The fair value of the convertible note was determined by using hybrid method that includes conversion scenario and liquidation scenario taking into account, inter alia, a debt discount rate of 28.65 %. The fair value of the July 30 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock price volatility of 122.8 % and risk-free interest rate of 4.78 %. The amount allocated to July 30 Warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price). Furthermore, it was determined that the embedded conversion feature and embedded redemption feature are required to be bifurcated from the host loan instrument. The fair value of the bifurcated derivatives was determined by the management using the assistance of an external appraiser in a total amount of $ 35 upon initial recognition and in subsequent periods as derivative liability at fair value through profit and loss. The remaining amount of $ 1,415 was allocated to the host loan instrument which in subsequent periods is accounted for using the effective interest method over the term of the loan, until its stated maturity. The following tabular presentation reflects the reconciliation of the carrying amount of the July 30 Note during the period of nine months ended September 30, 2024: SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES Nine-month period ended September 30, 2024 (Unaudited) Open balance $ - Total proceeds received 4,000 Total proceeds allocated to July 30 Warrants at initial recognition ( 2,550 ) Total proceeds allocated to embedded redemption feature at initial recognition ( 35 ) Amortization of discount and interest expenses related to July 30 Note (Note 5 below) 309 Ending balance $ 1,724 The following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption feature during the period of nine months ended September 30, 2024: SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE Nine-month period ended September 30, 2024 (Unaudited) Open balance $ - Proceeds allocated to embedded redemption feature at initial recognition 35 Revaluation expenses related to embedded redemption feature (Note 5 below) 2 Ending balance $ 37 On September 24, 2024, the Company held a special meeting of its stockholders under which shares of common stock issuable by the Company upon conversion of the July 30 Note and exercise of the July 30 Warrants has been approved. However, through September 30, 2024, July 30 Holder has not elected to trigger the conversion of July 30 Note or the exercise of the July 30 Warrants into shares of common stock. 18 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) I. August 23 Conversion On August 23, 2024 (the “Commitment Date”), the Company and two of June 27 Investors entered into conversion agreement, under which the Company agreed to convert the principal nominal amount plus any accrued but unpaid interest pursuant to each of June 27 Notes, totalling approximately $ 20 each (the “Debt”), held by the Investors to Common Stock at a conversion price of $ 1.02 per share. On October 15, 2024, the Company issued 19,682 shares of common stock for each of the two of the June 27 Investors in respect of each respective Debt converted. In satisfaction of the Debt, the Company also issued to each of the two June 27 Investors three warrants (each an “August 23 Warrant”). Each August 23 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The August 23 Warrants are exercisable for cash only and have no price-based antidilution. The first August 23 Warrant is for 10,707 shares of Common Stock and is exercisable at $ 1.875 per share. The second August 23 Warrant is for 7,648 shares of Common Stock, exercisable at $ 2.625 per share. The third August 23 Warrant is for 5,948 shares of Common Stock, exercisable at $ 3.375 per share. The above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to the June 27 Investors (i.e. shares of common stock and August 23 Warrants) are eligible for equity classification and thus both have been recorded as part of the permanent equity based on the total fair value of $ 238 at the Commitment Date. The difference between the fair value of these equity instruments and the carrying amount of each of the respective Debt at the Commitment Date amounted to $ 11 was charged immediately to the finance expenses (see also Note 5 below). During the period commencing the issuance date through September 30, 2024, none of the August 23 Warrants have been exercised. J. Sep 5 Conversion On September 5, 2024 (the “Commitment Date”), the Company and one of June 27 Investors and July 18 Investors entered into a conversion agreement, under which the Company agreed to convert outstanding board fees amounted $ 113 and the principal nominal amount plus any accrued but unpaid interest pursuant to June 27 Note and July 18 Note, totalling $ 146 (referring together as a “Debt”), held by the Investor to Common Stock at a conversion price of $ 1.02 per share. On October 15, 2024, the Company issued 254,226 shares of common stock for the June 27 Investor in respect of the Debt converted. In satisfaction of the Debt, the Company also issued to June 27 Investor and July 18 Investor three warrants (each an “September 5 Warrant”). Each September 5 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The September 5 Warrants are exercisable for cash only and have no price-based antidilution. The first September 5 Warrant is for 138,299 shares of Common Stock and is exercisable at $ 1.875 per share. The second September 5 Warrant is for 98,785 shares of Common Stock, exercisable at $ 2.625 per share. The third September 5 Warrant is for 76,833 shares of Common Stock, exercisable at $ 3.375 per share. The above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to the July 18 Investor (i.e. shares of common stock and September 5 Warrants) are eligible for equity classification and thus both have been recorded as part of permanent equity based on the total fair value of $ 1,505 at the Commitment Date. The difference between the fair value of these equity instruments and the carrying amount of the Debt at the Commitment Date amounted to $ 227 was charged immediately to the finance expenses (see also Note 5 below). During the period commencing the issuance date through September 30, 2024, none of the September 5 Warrants have been exercised. 19 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES A. In 2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately $ 93 (NIS 420,000 ), for develop a non-invasive blood glucose monitor (the “Development Plan”). Integrity Israel is required to pay royalties to IIA at a rate ranging between 3 - 5 % of the proceeds from sale of the Company’s products arising from the Development Plan up to an amount equal to $ 93 , plus interest at LIBOR from the grant date. As to replacement of the LIBOR benchmark rate, even though the IIA has not declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of September 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately $ 73 , excluding interest. Such contingent obligation has no expiration date. B. On October 7, 2022 (“the Closing Date”), the Company entered into Intellectual Property Purchase Agreement (the “Agreement”) with Paul Goode, which is the Company’s Chief Executive Officer (the “Seller”), under which it was agreed that on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller sold and assigned to the Company, all of Seller’s right, title and interest in and to the following assets, properties and rights (collectively, the “Purchased Assets”): (i) all rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the “Conveyed Intellectual Property”); and (ii) all the goodwill relating to the Purchased Assets. In consideration for the sale of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash in the amount of one dollar and obligated to issue up to 200,000 shares of Common Stock to be issued based upon specified performance milestones as set forth in the Agreement (the “Purchase Price”). In addition, if upon the final issuance, the aggregate 200,000 shares represent less than 1.5 % of the then outstanding Common Stock of the Company, the final issuance will include such number of additional shares so that the total aggregate issuance equals 1.5 % of the outstanding shares (the “True-Up Shares”). All shares of Common Stock of the Company that will be issued under the agreement shall be (i) restricted over a limited period as defined in the Agreement and (ii) subject to the lockup provisions. When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted for as asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (“IPR&D”) to be used in research and development projects which have been determined not to have alternative future use at the acquisition date, is expensed immediately. At the Closing Date, it was determined that the asset acquisition represents the purchase of IPR&D with no alternative future use. However, the achievement of each of the performance milestones is considered as a contingent event outside the Company’s control and thus the contingent consideration which is equal to the fair value of the Purchase Price as measured at the Closing Date will be recognized when it becomes probable that each target will be achieved within the reasonable period. Such additional contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is resolved. In June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As a result, upon the date of the fulfilment of the first performance milestone the Company was committed to issue 20,000 restricted shares to the Seller. Accordingly, the Company recorded an amount of $ 131 as research and development expenses with a similar amount as an increase to additional paid-in capital. The first performance milestone shares were issued on February 6, 2024. In May 2024, the Company achieved the second performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As result, the Company is committed to issue 30,000 restricted shares to the Seller. Accordingly, the Company recorded stock-based compensation expenses amounted to $ 192 which represents the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate of 30 % over the applicable restriction period. As of September 30, 2024, the second performance milestone shares were not yet issued. As of September 30, 2024, the achievement of all other remaining performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof. 20 GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) NOTE 5 - FINANCE (INCOME) EXPENSES, NET SCHEDULE OF FINANCE EXPENSES Three-month period ended September 30, Nine-month period ended September 30, 2024 2023 2024 2023 Unaudited Unaudited Discount amortization and interest expenses related to June 27 Notes $ 16 $ - $ 16 $ - Interest expenses related to July 18 Notes 5 - 5 - Discount amortization and interest expenses related to July 30 Note 309 - 309 - Revaluation expenses related to derivative financial liabilities 2 - 2 - Revaluation expenses incurred from settlement of financial liabilities 1,505 - 1,505 - Interest on bank deposits ( 7 ) ( 1 ) ( 38 ) ( 2 ) Exchange rate differentials, bank commissions and miscellaneous 18 - 23 - Finance (income) expenses, net $ 1,848 $ ( 1 ) $ 1,822 $ ( 2 ) NOTE 6 - SUBSEQUENT EVENTS Management evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any other significant subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Completion of underwritten U.S. public offering On November 12, 2024, the Company completed a public offering (the “Offering”) under which the Company received gross proceeds of $ 10,000 in exchange for issuance of an aggregate of (i) 2,437,340 shares (the “Shares”) of its Common Stock, (ii) 4,756,900 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 4,756,900 shares of Common Stock (the “Pre-Funded Warrant Shares”) in lieu of Shares, (iii) Series A Warrants (the “Series A Warrants”) to purchase up to 7,194,240 shares of Common Stock (the “Series A Warrant Shares”) and (iv) Series B Warrants (the “Series B Warrants” and, together with the Series A Warrants, the “Common Warrants”) to purchase up to 7,194,240 shares of Common Stock (“the “Series B Warrant Shares” together with the Series A Warrant Shares, the “Warrant Shares”). Each Share or Pre-Funded Warrant, as applicable, was sold together with one Series A Warrant to purchase one share of Common Stock and one Series B Warrant to purchase one Common Share. The public offering price for each Share and accompanying Common Warrants was $ 1.39 , and the public offering price for each Pre-Funded Warrant and accompanying Common Warrants was $ 1.389 (the “Offering Price”). The Pre-Funded Warrants have an exercise price of $ 0.001 per share, are exercisable immediately and expire when exercised in full. Each Series A Common Warrant will have an exercise price per share of $ 1.81 and will be exercisable beginning on the date on which Stockholder Approval (as defined below) is received and deemed effective (the “Initial Exercise Date” or the “Stockholder Approval Date”). The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B Warrants will have an exercise price per share of $ 1.81 and will be exercisable beginning on the Initial Exercise Date. The Series B Warrants will expire on the two and one-half year anniversary of the Initial Exercise Date. The issuance of Common Warrant Shares upon exercise of the Common Warrants is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC (“Nasdaq”) (“Stockholder Approval” and the date on which Stockholder Approval is received and deemed effective, the “Stockholder Approval Date”). The exercise price of Series A Warrants and Series B Warrants is subject to certain adjustments. If at the time of exercise there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Series A Warrants Shares and Series B Warrant Shares to the holders, then the Series A Warrants and Series B Warrants may also be exercised, in whole or in part, at such time by means of a “cashless exercise”. In addition, the holders are entitled to an option to require the Company to purchase the Series A Warrants and Series B Warrants for cash in an amount equal to their Black-Scholes Option Pricing Model value, in the event that certain fundamental transactions (which some of them are not considered solely within the control of the Company) as defined in the Series B Warrants agreement, occur. Additionally, holders of Series B Warrants may also effect an “alternative cashless exercise” at any time while the Series B Warrants are outstanding following the Initial Exercise Date. Under the alternate cashless exercise option, the holder of the Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cashless exercise of the Series B Warrant and (ii) 3.0. Total incremental and direct issuance costs are estimated at the total amount of $ 1,127 . The closing of the public offering occurred on November 14, 2024 (the “Closing Date”). In a private placement offering completed concurrently with the completion of the public offering, the July 30 Investor voluntarily converted approximately $ 4,089 of Debt, which represents the outstanding minimal amount of principal and accrued interest under the July 30 Note as of November 12, 2024, on substantially the same terms as the public offering, resulting in the issuance of 2,640,717 shares of Common Stock (plus 2,640,717 accompanying Series A Warrants and 2,640,717 accompanying Series B Common Warrants), based on a conversion price of $ 1.55 per share. 21